CN116568301A - 用于治疗疾病的双环化合物及其用途 - Google Patents

用于治疗疾病的双环化合物及其用途 Download PDF

Info

Publication number
CN116568301A
CN116568301A CN202180079749.8A CN202180079749A CN116568301A CN 116568301 A CN116568301 A CN 116568301A CN 202180079749 A CN202180079749 A CN 202180079749A CN 116568301 A CN116568301 A CN 116568301A
Authority
CN
China
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
alkyl
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180079749.8A
Other languages
English (en)
Chinese (zh)
Inventor
L·卡瓦斯
K·丘奇
R·泰勒
J·约翰斯顿
D·波特曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yasina Pharmaceutical Co
Original Assignee
Yasina Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yasina Pharmaceutical Co filed Critical Yasina Pharmaceutical Co
Priority to CN202411623883.1A priority Critical patent/CN119684295A/zh
Publication of CN116568301A publication Critical patent/CN116568301A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202180079749.8A 2020-11-02 2021-11-01 用于治疗疾病的双环化合物及其用途 Pending CN116568301A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202411623883.1A CN119684295A (zh) 2020-11-02 2021-11-01 用于治疗疾病的双环化合物及其用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063108660P 2020-11-02 2020-11-02
US63/108,660 2020-11-02
PCT/US2021/057563 WO2022094400A1 (en) 2020-11-02 2021-11-01 Bicyclic compounds and uses thereof for the treatment of diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202411623883.1A Division CN119684295A (zh) 2020-11-02 2021-11-01 用于治疗疾病的双环化合物及其用途

Publications (1)

Publication Number Publication Date
CN116568301A true CN116568301A (zh) 2023-08-08

Family

ID=81384389

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202180079749.8A Pending CN116568301A (zh) 2020-11-02 2021-11-01 用于治疗疾病的双环化合物及其用途
CN202411623883.1A Pending CN119684295A (zh) 2020-11-02 2021-11-01 用于治疗疾病的双环化合物及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202411623883.1A Pending CN119684295A (zh) 2020-11-02 2021-11-01 用于治疗疾病的双环化合物及其用途

Country Status (13)

Country Link
US (1) US20240025903A1 (cg-RX-API-DMAC7.html)
EP (1) EP4236944A4 (cg-RX-API-DMAC7.html)
JP (1) JP7884275B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230104191A (cg-RX-API-DMAC7.html)
CN (2) CN116568301A (cg-RX-API-DMAC7.html)
AR (1) AR124637A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021371026A1 (cg-RX-API-DMAC7.html)
CA (1) CA3196582A1 (cg-RX-API-DMAC7.html)
CL (2) CL2023001195A1 (cg-RX-API-DMAC7.html)
IL (1) IL302465A (cg-RX-API-DMAC7.html)
MX (1) MX2023004942A (cg-RX-API-DMAC7.html)
TW (1) TWI918751B (cg-RX-API-DMAC7.html)
WO (1) WO2022094400A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL313039A (en) * 2021-12-17 2024-07-01 Athira Pharma Inc Uses of bicyclic compounds for the treatment of diseases
KR20250005323A (ko) * 2022-05-04 2025-01-09 아티라 파마, 인코포레이티드 신경병증을 치료하는 방법
US20250275976A1 (en) * 2022-05-04 2025-09-04 Athira Pharma, Inc. Methods of Treating Neuroinflammatory Conditions
JP2025538382A (ja) 2022-11-18 2025-11-28 アティラ・ファーマ・インコーポレイテッド 炎症病態を治療する方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184223B1 (en) * 1995-10-27 2001-02-06 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
WO2004035587A1 (en) 2002-10-17 2004-04-29 Myriad Genetics, Inc. Reverse-turn mimetics and composition and methods relating thereto
US7192976B2 (en) * 2002-12-21 2007-03-20 Angion Biomedica Corporation Small molecule modulators of hepatocyte growth factor (scatter factor) activity
WO2006036981A2 (en) * 2004-09-28 2006-04-06 Angion Biomedica Corp. Small molecule modulators of cytokine activity
US7879898B1 (en) * 2006-02-14 2011-02-01 Angion Biomedica Corp. Hepatocyte growth factor pathway activators in chronic obstructive pulmonary disease
EP1947085A1 (en) * 2007-01-19 2008-07-23 Laboratorios del Dr. Esteve S.A. Substituted indole sulfonamide compounds, their preparation and use as medicaments
US8691819B2 (en) * 2008-10-14 2014-04-08 Prism Biolab Corporation Alpha helix mimetic compositions for treating cancer and other CBP/catenin-mediated diseases and conditions
US20160074400A1 (en) * 2012-08-06 2016-03-17 University Of Southern California Wnt modulators for the protection, mitigation and treatment of radiation injury
EP3366687B1 (en) * 2015-09-18 2020-04-29 National University Corporation Tottori University Suppression and regeneration promoting effect of low molecular weight compound on cancer and fibrosis

Also Published As

Publication number Publication date
EP4236944A1 (en) 2023-09-06
TWI918751B (zh) 2026-03-21
CL2024000340A1 (es) 2024-08-16
US20240025903A1 (en) 2024-01-25
CN119684295A (zh) 2025-03-25
CA3196582A1 (en) 2022-05-05
AU2021371026A1 (en) 2023-06-15
JP2023550543A (ja) 2023-12-01
AU2021371026A9 (en) 2024-04-18
JP7884275B2 (ja) 2026-07-03
KR20230104191A (ko) 2023-07-07
AR124637A1 (es) 2023-04-19
IL302465A (en) 2023-06-01
CL2023001195A1 (es) 2023-10-20
TW202233622A (zh) 2022-09-01
MX2023004942A (es) 2023-07-06
EP4236944A4 (en) 2024-09-04
WO2022094400A1 (en) 2022-05-05

Similar Documents

Publication Publication Date Title
CN119684295A (zh) 用于治疗疾病的双环化合物及其用途
CN107001378A (zh) 吡咯并嘧啶化合物
EP4598907A1 (en) Phenyl oxy amide kinase inhibitors
KR20240121239A (ko) 질환 치료를 위한 이환식 화합물의 용도
JP2025515045A (ja) 神経炎症病態を治療する方法
EP4518866A1 (en) Methods of treating fibrosis
CN118382441A (zh) 双环化合物用于治疗疾病的用途
HK40122844A (en) Bicyclic compounds and uses thereof for the treatment of diseases
EA049703B1 (ru) Бициклические соединения и их применение для лечения заболеваний
HK40113746A (en) Uses of bicyclic compounds for the treatment of diseases
HK40097563A (en) Bicyclic compounds and uses thereof for the treatment of diseases
CN119300834A (zh) 治疗神经病变的方法
EA050745B1 (ru) Применение бициклических соединений для лечения заболеваний

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40097563

Country of ref document: HK

CB02 Change of applicant information
CB02 Change of applicant information

Country or region after: U.S.A.

Address after: Washington State

Applicant after: Liona Biotechnology Co.,Ltd.

Address before: Washington State

Applicant before: Yasina Pharmaceutical Co.

Country or region before: U.S.A.